Diagnosis of Cardiac Amyloidosis: Clinical and Echocardiographic Features


Purpose of Review

This review is geared to address the various forms of amyloidosis which have cardiac involvement and discuss the echocardiographic findings that may be present in patients with cardiac amyloidosis.

Recent Findings

The use of echocardiography has revolutionized the diagnosis of cardiac amyloidosis. The diagnosis is often first suspected due to characteristic echocardiographic findings. Although no single finding is pathognomonic, there are a constellation of features that point to the diagnosis including increased left and right ventricular wall thickness, thickened cardiac valves and atrial walls, and a pericardial effusion. Alterations in diastolic function with evidence of elevated filling pressures are common. The use of myocardial strain imaging has allowed for earlier detection of cardiac amyloidosis and has revealed a distinctive pattern, sometimes suggesting the diagnosis when more classic findings are subtle or absent. Multiple echocardiographic findings have been found to be prognostic in cardiac amyloid. Using current techniques, functional measures such as myocardial strain and stroke volume index are more powerful predictors of outcome than myocardial thickness. While other imaging modalities are complementary including cardiac magnetic resonance imaging and nuclear medicine scintigraphy techniques using bone tracers, echocardiography remains a mainstay in the diagnosis and follow-up of patients with cardiac amyloidosis.


Echocardiography is a critical tool in the evaluation of the patient with heart failure, as well as those with unexplained chest pain and arrhythmias. Key findings on an echocardiogram can help alert the clinician to the presence of cardiac amyloidosis. The degree of cardiac dysfunction in a patient with systemic amyloidosis correlates with prognosis. Recognition of subtle echocardiographic findings may allow for earlier and more aggressive treatment to improve overall mortality in patients with cardiac amyloidosis.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.

    Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol. 2015;24(6):343–50.

    CAS  Article  Google Scholar 

  2. 2.

    • Grogan M, Dispenzieri A. Natural history and therapy of AL cardiac amyloidosis. Heart Fail Rev. 2015;20(2):155–62 Comprehensive review of light chain cardiac amyloidosis with focus on clinical and imaging findings as well as treatment options.

    CAS  Article  Google Scholar 

  3. 3.

    Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66(21):2451–66.

    CAS  Article  Google Scholar 

  4. 4.

    Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014–20.

    Article  Google Scholar 

  5. 5.

    Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047–60.

    Article  Google Scholar 

  6. 6.

    Grogan M, Dispenzieri A, Gertz MA. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart. 2017;103(14):1065–72.

    CAS  Article  Google Scholar 

  7. 7.

    Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91(2):141–57.

    CAS  Article  Google Scholar 

  8. 8.

    Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203–12.

    CAS  Article  Google Scholar 

  9. 9.

    Cornwell GG III, Westermark P. Senile amyloidosis: a protean manifestation of the aging process. J Clin Pathol. 1980;33(12):1146–52.

    Article  Google Scholar 

  10. 10.

    Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Failure. 2014;2(2):113–22.

    Article  Google Scholar 

  11. 11.

    • Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–94 Discussion about the role of ATTRwt amyloidosis as an etiology for the diagnosis of heart failure with preserved ejection fraction (itself a complex clinical dilemma).

    CAS  Article  Google Scholar 

  12. 12.

    • Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357–77 Review of the approach to diagnosis cardiac amyloidosis particularly as it related to various presentations.

    Article  Google Scholar 

  13. 13.

    Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–12.

    CAS  Article  Google Scholar 

  14. 14.

    Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR III, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957–9.

    CAS  Article  Google Scholar 

  15. 15.

    Chamarthi B, Dubrey SW, Cha K, Skinner M, Falk RH. Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol. 1997;80(9):1242–5.

    CAS  Article  Google Scholar 

  16. 16.

    Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2(2):e000098.

    Article  Google Scholar 

  17. 17.

    Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation. 2016;133(3):282–90.

    CAS  Article  Google Scholar 

  18. 18.

    Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007;116(21):2420–6.

    Article  Google Scholar 

  19. 19.

    Zubkov AY, Rabinstein AA, Dispenzieri A, Wijdicks EF. Primary systemic amyloidosis with ischemic stroke as a presenting complication. Neurology. 2007;69(11):1136–41.

    Article  Google Scholar 

  20. 20.

    Falk RH, Alexander KM, Liao R, Dorbala S. AL (light-chain) cardiac amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016;68(12):1323–41.

    Article  Google Scholar 

  21. 21.

    Siddiqi OK, Sanchorawala V, Ruberg FL. Echocardiography and survival in light chain cardiac amyloidosis: back to basics. Circ Cardiovasc Imaging. 2018;11(5):e007826.

    Article  Google Scholar 

  22. 22.

    Mookadam F, Haley JH, Olson LJ, Cikes M, Mookadam M. Dynamic left ventricular outflow tract obstruction in senile cardiac amyloidosis. Eur J Echocardiogr. 2006;7(6):465–8.

    Article  Google Scholar 

  23. 23.

    Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005;95(4):535–7.

    Article  Google Scholar 

  24. 24.

    Suresh R, Grogan M, Maleszewski JJ, Pellikka PA, Hanna M, Dispenzieri A, et al. Advanced cardiac amyloidosis associated with normal interventricular septal thickness: an uncommon presentation of infiltrative cardiomyopathy. J Am Soc Echocardiogr. 2014;27(4):440–7.

    Article  Google Scholar 

  25. 25.

    Fealey ME, Edwards WD, Buadi FK, Syed IS, Grogan M. Echocardiographic features of cardiac amyloidosis presenting as endomyocardial disease in a 54-year-old male. J Cardiol. 2009;54(1):162–6.

    Article  Google Scholar 

  26. 26.

    Klein AL, Hatle LK, Taliercio CP, Oh JK, Kyle RA, Gertz MA, et al. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation. 1991;83(3):808–16.

    CAS  Article  Google Scholar 

  27. 27.

    • Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38(38):2879–87 Paper illustrating two complex conditions which may occur in the elderly patient: severe aortic stenosis and cardiac amyloidosis. How the presence of cardiac amyloidosis may result in low flow, low gradient aortic stenosis.

    Article  Google Scholar 

  28. 28.

    Cirulis MM, Emerson LL, Bull DA, Hatton N, Nativi-Nicolai J, Hildebrandt GC, et al. Pulmonary arterial hypertension in primary amyloidosis. Pulm Circ. 2016;6(2):244–8.

    CAS  Article  Google Scholar 

  29. 29.

    Milani P, Dispenzieri A, Scott CG, Gertz MA, Perlini S, Mussinelli R, et al. Independent prognostic value of stroke volume index in patients with immunoglobulin light chain amyloidosis. Circ Cardiovasc Imaging. 2018;11(5):e006588.

    Article  Google Scholar 

  30. 30.

    Bellavia D, Abraham TP, Pellikka PA, Al-Zahrani GB, Dispenzieri A, Oh JK, et al. Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. J Am Soc Echocardiogr. 2007;20(10):1194–202.

    Article  Google Scholar 

  31. 31.

    Porciani MC, Lilli A, Perfetto F, Cappelli F, Massimiliano Rao C, Del Pace S, et al. Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis. Amyloid. 2009;16(2):63–70.

    Article  Google Scholar 

  32. 32.

    Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging. 2010;3(4):333–42.

    Article  Google Scholar 

  33. 33.

    • Barros-Gomes S, Williams B, Nhola LF, Grogan M, Maalouf JF, Dispenzieri A, et al. Prognosis of light chain amyloidosis with preserved LVEF: added value of 2D speckle-tracking echocardiography to the current prognostic staging system. JACC Cardiovasc Imaging. 2017;10(4):398–407 Discussion about the utility of strain imaging, along with other markers of cardiac amyloidosis, for prognostic determination.

    Article  Google Scholar 

  34. 34.

    Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014;129(18):1840–9.

    Article  Google Scholar 

  35. 35.

    Boynton SJ, Geske JB, Dispenzieri A, Syed IS, Hanson TJ, Grogan M, et al. LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis. JACC Cardiovasc Imaging. 2016;9(6):680–6.

    Article  Google Scholar 

  36. 36.

    Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):186–93.

    Article  Google Scholar 

  37. 37.

    Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010;3(2):155–64.

    Article  Google Scholar 

  38. 38.

    White JA, Kim HW, Shah D, Fine N, Kim KY, Wendell DC, et al. CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):143–56.

    Article  Google Scholar 

  39. 39.

    Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6(4):488–97.

    Article  Google Scholar 

  40. 40.

    Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6(1):34–9.

    Article  Google Scholar 

  41. 41.

    Rapezzi C, Guidalotti P, Salvi F, Riva L, Perugini E. Usefulness of 99mTc-DPD scintigraphy in cardiac amyloidosis. J Am Coll Cardiol. 2008;51(15):1509–10 author reply 10.

    Article  Google Scholar 

  42. 42.

    Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195–201.

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Rekha Mankad.

Ethics declarations

Conflict of Interest

Both authors declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of Topical Collection on Echocardiography

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mankad, R., Grogan, M. Diagnosis of Cardiac Amyloidosis: Clinical and Echocardiographic Features. Curr Cardiovasc Imaging Rep 11, 32 (2018). https://doi.org/10.1007/s12410-018-9472-2

Download citation


  • Cardiac amyloidosis
  • Diastolic dysfunction
  • Light chain
  • Transthyretin
  • Global longitudinal strain
  • Pyrophosphate